{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:42:27Z","timestamp":1786736547421,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pathol Microbiol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijpm.ijpm_136_19","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T03:44:27Z","timestamp":1582688667000},"page":"123","source":"Crossref","is-referenced-by-count":13,"title":["Quantitative real-time PCR assay with immunohistochemical evaluation of HER2\/neu oncogene in breast cancer patients and its correlation with clinicopathological findings"],"prefix":"10.4103","volume":"63","author":[{"given":"Nadia","family":"Gheni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0377-4929.279556-1","unstructured":"Society AAC. Selected cancers, Breast Cancer Facts and Figures 2016;2016:9-10."},{"key":"key-10.4103\/0377-4929.279556-2","first-page":"6","article-title":"Selected cancers, Breast (female).Cancer treatment and Survivorship Facts and [Figure 2016], [Figure 2017]","author":"2016","year":"2016","journal-title":""},{"key":"key-10.4103\/0377-4929.279556-3","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ijc.28150","article-title":"Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT\/BR9601 trial","author":"Ali","year":"2013","journal-title":"Int J Cancer"},{"key":"key-10.4103\/0377-4929.279556-4","first-page":"1","article-title":"Breast cancer prognostic classification in the molecular era: The role of histological grade","author":"Rakha","year":"2010","journal-title":"Breast Cancer Res"},{"key":"key-10.4103\/0377-4929.279556-5","first-page":"1","article-title":"Real-time PCR complements immunohistochemistry in the determination of HER-2\/neu status in breast cancer","author":"Nistor","year":"2006","journal-title":"BMC Clin Pathol"},{"key":"key-10.4103\/0377-4929.279556-6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"key-10.4103\/0377-4929.279556-7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.7314\/APJCP.2013.14.3.1655","article-title":"Quantification of HER-2\/neu gene in breast cancer patients using real time-polymerase chain reaction (Q-PCR) and correlation with immunohistochemistry findings","author":"Abdul","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"key-10.4103\/0377-4929.279556-8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1309\/8A2DJFT07NE6EWHE","article-title":"Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma","author":"Bofin","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"key-10.4103\/0377-4929.279556-9","first-page":"266","article-title":"c-erbB-2 (HER-2\/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients","author":"Riou","year":"2001","journal-title":"Int J Cancer"},{"key":"key-10.4103\/0377-4929.279556-10","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","article-title":"HER-2\/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas","author":"Press","year":"1997","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0377-4929.279556-11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0304-3835(94)90194-5","article-title":"ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer","author":"Borg","year":"1994","journal-title":"Cancer Lett"},{"key":"key-10.4103\/0377-4929.279556-12","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199405053301802","article-title":"c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer","author":"Muss","year":"1994","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0377-4929.279556-13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signaling network","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key-10.4103\/0377-4929.279556-14","doi-asserted-by":"crossref","unstructured":"Nahta R, Esteva FJ. Herceptin: Mechanisms of action and resistance. Cancer Lett 2006;232:123-38.","DOI":"10.1016\/j.canlet.2005.01.041"},{"key":"key-10.4103\/0377-4929.279556-15","first-page":"241","article-title":"American Society of Clinical Oncology; College of American Pathologists.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","author":"Wolff","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"key-10.4103\/0377-4929.279556-16","first-page":"929","article-title":"Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: A comparative methodological study using the Ventana BenchMark automated staining system and manual tests","author":"B\u00e1nkfalvi","year":"2004","journal-title":"Int J Oncol"},{"key":"key-10.4103\/0377-4929.279556-17","first-page":"63","article-title":"Detection and quantitation of HER-2\/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization","author":"Pauletti","year":"1996","journal-title":"Oncogene"},{"key":"key-10.4103\/0377-4929.279556-18","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1200\/JCO.2011.35.2245","article-title":"Clinical notice for American society of clinical oncology-college of American pathologists guideline recommendations on ER\/PgR and HER2 testing in breast cancer","author":"Hammond","year":"2011","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0377-4929.279556-19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1136\/jcp.2006.040287","article-title":"HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas","author":"Ricardo","year":"2007","journal-title":"J Clin Pathol"},{"key":"key-10.4103\/0377-4929.279556-20","first-page":"4454","article-title":"Immunohistochemical results of HER2\/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas","author":"Song","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"key-10.4103\/0377-4929.279556-21","first-page":"1703","article-title":"HER-2\/neu amplification determined by real-time quantitative PCR and its association with clinical outcome of breast cancer in Thailand","author":"Chariyalertsak","year":"2011","journal-title":"Asian Pac J Cancer Prev"},{"key":"key-10.4103\/0377-4929.279556-22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/GCO.0b013e328012980a","article-title":"HER2\/neu role in breast cancer: From a prognostic foe to a predictive friend","author":"Ferretti","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"key":"key-10.4103\/0377-4929.279556-23","first-page":"312","article-title":"Evaluation of HER-2\/neu status in breast cancer specimens using immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) assay","author":"Kalal","year":"2012","journal-title":"Indian J Med Res","ISSN":"https:\/\/id.crossref.org\/issn\/0971-5916","issn-type":"print"},{"key":"key-10.4103\/0377-4929.279556-24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2559.2005.02112.x","article-title":"Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2\/neu overexpression in human breast carcinomas","author":"Vanden","year":"2005","journal-title":"Histopathology"},{"key":"key-10.4103\/0377-4929.279556-25","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.clinbiochem.2006.06.001","article-title":"HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization","author":"Ntoulia","year":"2006","journal-title":"Clin Biochem"},{"key":"key-10.4103\/0377-4929.279556-26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3349\/ymj.2002.43.3.335","article-title":"Evaluation of HER2\/neu status by real-time quantitative PCR in breast cancer","author":"Kim","year":"2002","journal-title":"Yonsei Med J"},{"key":"key-10.4103\/0377-4929.279556-27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.molmed.2006.01.006","article-title":"Circulating tumor cells: The 'leukemic phase' of solid cancers","author":"Mocellin","year":"2006","journal-title":"Trends Mol Med"},{"key":"key-10.4103\/0377-4929.279556-28","first-page":"1","article-title":"Quantitative real-time RT-PCR and chromogenic in situ hybridization: Precise methods to detect HER-2 status in breast carcinoma","author":"Rosa","year":"2009","journal-title":"BMC Cancer"},{"key":"key-10.4103\/0377-4929.279556-29","first-page":"896","article-title":"Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer","author":"Ji","year":"2014","journal-title":"J Thorac Dis"},{"key":"key-10.4103\/0377-4929.279556-30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.critrevonc.2010.12.005","article-title":"Current technologies for HER2 testing in breast cancer","author":"Moelans","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"key-10.4103\/0377-4929.279556-31","first-page":"1","article-title":"HER-2 therapy.HER-2\/neu diagnostics in breast cancer","author":"Carney","year":"2007","journal-title":"Breast Cancer Res"},{"key":"key-10.4103\/0377-4929.279556-32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1373\/clinchem.2004.044305","article-title":"Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients","author":"Tse","year":"2005","journal-title":"Clin Chem"},{"key":"key-10.4103\/0377-4929.279556-33","first-page":"31","article-title":"Methods for evaluating HER2 status in breast cancer: Comparison of IHC, FISH, and real-time PCR analysis of formalin-fixed paraffin-embedded tissue","author":"Olsson","year":"2013","journal-title":"Pathol Lab Med Int"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:43:16Z","timestamp":1786732996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_136_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"alternative-id":["279556"],"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_136_19","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}